Forte Biosciences, Inc. (FBRX)

Market Cap	542.43M +660.9%
Revenue (ttm)	n/a
Net Income	-51.74M
EPS	-4.39
Shares Out	17.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,286
Open	30.38
Previous Close	30.65
Day's Range	29.92 - 32.85
52-Week Range	4.90 - 35.62
Beta	3.24
Analysts	Strong Buy
Price Target	67.00 (+120.25%)
Earnings Date	Mar 30, 2026

About FBRX

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Paul A. Wagner
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: FBRX
• Website: https://www.fortebiorx.com

Analyst Summary

According to 3 analysts, the average rating for FBRX stock is "Strong Buy." The 12-month stock price target is $67.0, which is an increase of 120.25% from the latest price.

Price Target

$67.0

(120.25% upside)

Analyst Consensus: Strong Buy